 The European Commission has approved a combination of Merck Co Incs NYSE: MRK Keytruda plus Eisai Co Ltds OTC: ESALY Lenvima for advanced or recurrent endometrial carcinoma. The approval covers adult patients who have disease progression on or following prior treatment with a platinumcontaining therapy in any setting and are not candidates for curative surgery or radiation. 